Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>BOCOM International Lowers Hansoh Pharmaceutical (03692.HK) TP to HKD44.5 as Last Year's Results Exceeded Expectations
Recommend 1 Positive 2 Negative 0 |
||||
|
||||
|
BOCOM International published a report stating that Hansoh Pharmaceutical (03692.HK) exceeded expectations with its 2025 results, and its innovative drug sales and BD are expected to continue high growth in 2026. The company's full-year revenue and net profit grew by 23% and 27% YoY to RMB15.03 billion and RMB5.56 billion, respectively, surpassing both the firm's and market expectations. Looking ahead to 2026, management guides for double-digit growth in product sales and collaboration income, with R&D investment expected to increase by more than 30%. In the long term, the company anticipates stable growth in Ameile sales, maintaining a peak sales guidance of RMB8 billion before 2030. The report noted that Hansoh Pharmaceutical's mid-to-late stage pipeline in 2026 is flourishing with abundant catalysts. Key pipelines are progressing steadily: 1) HS-20093 (B7H3ADC): Will read out 2LSCLC and 2L osteosarcoma China Phase III data and apply for listing within the year; 2L non-squamous NSCLC Phase III has recently started, and global 2LSCLC Phase III enrollment is ongoing; 2) HS-20089 (B7H4ADC): GSK has initiated Phase III for advanced endometrial and ovarian cancers, with I/II data to be read out within the year; 3) HS-20094 (GLP-1/GIP): Expected to publish weight loss Phase III data and apply for listing in 2H26, with China approval in 2H27; 4) HS10374 (TYK2 inhibitor): Plans to read out China psoriasis Phase III data and apply for listing within the year. Additionally, nine products will initiate Phase III or pivotal registration clinical trials this year. The firm maintains a "Buy" rating on Hansoh Pharmaceutical but lowers the target price to HKD44.5. (ha/w) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
URL: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
